I-AASraw ivelisa i-NMN kunye ne-NRC powders ngobuninzi!

ICabozantinib

Akukho kalo Udidi:

I-Cabozantinib Powder, ethengiswa phantsi kwegama lophawu lweCometriq kunye neCabometyx, lunyango olusetyenziselwa ukunyanga umhlaza we-thyroid, i-renal cell carcinoma kunye ne-hepatocellular carcinoma. Yinto encinci ye-molecule inhibitor ye-tyrosine kinases c-Met kunye ne-VEGFR2, kwaye ikwathintela i-AXL kunye neRET. Yafunyanwa kwaye yaphuhliswa ngu-Exelixis Inc.

Ingcaciso yeMveliso

Iimpawu ezisisiseko

Igama lemveliso ICabozantinib powder
Inani leCAS 849217-68-1
I-Molecular Formula C28H24FN3O5
Ubunzima beMolar 501.514
Iintetho ezifanayo XL184, BMS907351;

Ikhabhathi;

ICometriq;

ICabozanix.

Kubonakala Powstalline powder
Ukugcina nokuPhatha Yigcine kubushushu begumbi kwaye kude nobushushu obuninzi kunye nokufuma.

 

Umgubo weCabozantinibinkcazelo

I-Cabozantinib Powder, ethengiswa phantsi kwegama lophawu lweCometriq kunye neCabometyx, lunyango olusetyenziselwa ukunyanga umhlaza we-thyroid, i-renal cell carcinoma kunye ne-hepatocellular carcinoma. Yinto encinci ye-molecule inhibitor ye-tyrosine kinases c-Met kunye ne-VEGFR2, kwaye ikwathintela i-AXL kunye neRET. Yafunyanwa kwaye yaphuhliswa ngu-Exelixis Inc.

Ngo-Novemba ngo-2012, i-cabozantinib powder (Cometriq) ekwakhiweni kwayo njenge-capsule yamkelwe yi-US Food and Drug Administration (FDA) phantsi kwegama elithi Cometriq yokunyanga abaguli abanomhlaza we-thyroid. Ifom ye-capsule yamkelwa kwi-European Union ngenjongo efanayo kwi-2014.

Nge-Epreli ka-2016, i-FDA yanika imvume yokuthengisa ukwenziwa kwethebhulethi (i-Cabometyx) njengonyango lwesibini lomhlaza wezintso [8] [9] kwaye kwavunywa okufanayo kwi-European Union ngo-Septemba waloo nyaka. zinemixube eyahlukeneyo kwaye azitshintshi.

 

ICabozantinib Powder Mechanism of Action

I-Cabozantinib Powder inqanda oku kulandelayo:

 

Umgubo weCabozantinib isicelo

ICabozantinib powder isetyenziswa ngeendlela ezimbini. Ifom ye-capsule isetyenziswa ukusukela ngo-2012 ukunyanga umhlaza we-medullary cancer kunye nefomathi yethebhulethi esetyenzisiweyo ukusukela ngo-2016 njengonyango lwesibini lonyango lwe-renal cell carcinoma.

 

Umgubo weCabozantinib Iziphumo ebezingalindelekanga kunye nesilumkiso

I-Cabozantinib powder ayizange ihlolwe kwabasetyhini abakhulelweyo; ibangela ingozi kwimveku engekazalwa ngeempuku. Abafazi abakhulelweyo akufuneki bathathe eli chiza, kwaye abasetyhini akufuneki bakhulelwe ngelixa belithatha. Ayaziwa ukuba i-cabozantinib powder ikhutshwe kubisi lwebele.Ichiza kufuneka lisetyenziswe ngononophelo kubantu abanembali yeengxaki zesingqisho sentliziyo, kubandakanya ixesha elide le-QT.

E-US, i-capsule formulation (Cometriq) inebhokisi emnyama elumkisa ngomngcipheko wemingxunya eyenzeka esiswini okanye emathunjini kunye nokwenziwa kweefistula (iitonela eziphakathi kwendlela ye-GI kunye nolusu). Ibhokisi emnyama ikwalumkisa ngomngcipheko wokopha okungalawulekiyo. Ukwenziwa kwethebhulethi (Cabometyx) kulumkisa ngezi ziphumo.

Iilebheli zikwalumkisa ngomngcipheko wamahlwili owenza kwaye abangele ukuhlaselwa yintliziyo okanye ukubetha, uxinzelelo lwegazi oluphezulu kubandakanya ingxaki yoxinzelelo lwegazi, i-osteonecrosis yomhlathi, urhudo oluqatha, ulusu luthambekele ezintendeni nasezandleni, isifo esineentloko, ukudideka, ukulahleka kombono , kunye nokuxhuzula, kunye neprotein ebonakalayo kumchamo

Iziphumo ezibi kakhulu eziqhelekileyo (ngaphezulu kwe-10% yabantu) zibandakanya ukuncipha kokutya; i-calcium ephantsi, i-potassium, i-phosphate kunye ne-magnesium; amanqanaba aphezulu e-bilirubin; uluvo olugwenxa lokungcamla, intloko ebuhlungu, kunye nesiyezi; igazi elonyukayo; ukuva okugqwethekileyo, iindlebe kunye nomqala obuhlungu; urhudo, isicaphucaphu, ukuqhina, ukugabha, iintlungu zesisu kunye nokudumba kwesisu, nokudumba komlomo kunye nemilebe kunye nokutsha okuvuthayo emlonyeni; Ulusu lucoca iintende kunye neenyawo, utshintsho lombala weenwele kunye nokulahleka kweenwele, irhashalala, ulusu olomileyo kunye nolusu lubomvu intlungu edibeneyo kunye ne-muscle spasms; ukudinwa nokuba buthathaka; ukwehla kobunzima, ii-transaminase eziphakamileyo, amanqanaba aphezulu e-cholesterol, kunye nelahleko yeeseli ezibomvu nezimhlophe zegazi.

 

isingqiniso

[1] "I-Cabozantinib powder Sebenzisa ngexesha lokukhulelwa". Iziyobisi.com. 30 Matshi 2020. Ibuyisiwe 23 Septemba 2020.

[2] “ICabometyx- cabozantinib powder ithebhulethi”. Yonke imihla. 21 kweyeKhala 2020. Ifunyanwa 23 Septemba 2020.

[3] "ICometriq- cabozantinib powder kit iCometriq- cabozantinib powder capsule". Yonke imihla. I-11 kaFebruwari 2020. Ibuyisiwe nge-23 Septemba 2020.

[4] "ICometriq EPAR". I-Arhente yamaYeza yaseYurophu (EMA). Ukufunyanwa kwe-23 ngoSeptemba 2020.

[5] "ICabometyx EPAR". IArhente yamaYeza yaseYurophu. 17 Septemba 2018. Ibuyiswe nge-23 Septemba 2020.

[6] "I-FDA iyayamkela iCometriq ukunyanga uhlobo olunqabileyo lomhlaza wedlala lengqula" (Ukhuphelo lweendaba). Ulawulo lwezoKutya kunye noLawulo lweziyobisi (FDA). Nge-29 kaNovemba ngo-2012. Kugciniwe ukusuka kwinto yokuqala ngoJulayi 7, 2014.